There is a need for a safe and effective tularemia vaccine, which can be licensed for general use to address potential bioterrorism threats.
LVS has been successfully used in Europe and the USA to protect tularemia researchers against infection with Type A strains (Oyston and Quarry, 2005, Conlan, 2004 and Titball and Oyston, 2003).